Bright Futures Wealth Management LLC. Lowers Stake in Johnson & Johnson (NYSE:JNJ)

Bright Futures Wealth Management LLC. decreased its position in Johnson & Johnson (NYSE:JNJ) by 55.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,575 shares of the company’s stock after selling 1,931 shares during the period. Bright Futures Wealth Management LLC.’s holdings in Johnson & Johnson were worth $238,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. AMF Tjanstepension AB grew its stake in Johnson & Johnson by 14.2% during the third quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock worth $68,985,000 after buying an additional 52,997 shares during the period. Alpha Financial Partners LLC purchased a new position in shares of Johnson & Johnson in the third quarter valued at $209,000. Wealth Group Ltd. purchased a new position in shares of Johnson & Johnson in the third quarter valued at $213,000. Swedbank AB boosted its stake in shares of Johnson & Johnson by 5.3% in the third quarter. Swedbank AB now owns 2,215,108 shares of the company’s stock valued at $358,980,000 after purchasing an additional 111,570 shares during the period. Finally, Schaper Benz & Wise Investment Counsel Inc. WI boosted its stake in shares of Johnson & Johnson by 1.8% in the third quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 97,483 shares of the company’s stock valued at $15,798,000 after purchasing an additional 1,768 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.7 %

Shares of JNJ stock opened at $156.20 on Tuesday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The business’s 50 day moving average is $147.87 and its two-hundred day moving average is $155.95. The company has a market cap of $376.08 billion, a PE ratio of 23.49, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the company posted $2.29 earnings per share. Equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.18%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Insider Buying and Selling

In related news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently issued reports on JNJ shares. Guggenheim upped their price target on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a report on Monday, February 3rd. Wells Fargo & Company cut their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Barclays increased their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Raymond James lowered their price target on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Finally, Bank of America lowered their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.